Contraindications for Ranexa (Ranolazine)
Ranexa is absolutely contraindicated in three specific clinical situations: patients taking strong CYP3A inhibitors, patients taking CYP3A inducers, and patients with liver cirrhosis. 1
Absolute Contraindications
1. Strong CYP3A Inhibitors
Do not prescribe Ranexa to patients taking strong CYP3A inhibitors, as these dramatically increase ranolazine exposure and risk of QT prolongation 1. Strong inhibitors include:
- Ketoconazole (increases ranolazine AUC by 3.9-fold) 2
- Posaconazole (increases AUC by 2.8-3.9-fold, with prolonged washout effects lasting 7-14 days after discontinuation) 3
- Other azole antifungals
- HIV protease inhibitors
- Clarithromycin
Critical pitfall: Even after stopping a strong CYP3A inhibitor like posaconazole, the drug interaction persists for up to 2 weeks. If ranolazine must be resumed, limit dosing to 500 mg twice daily for 7 days in normal-weight patients (BMI 18.5-24.9) or 12 days in obese patients (BMI ≥35) 3.
2. CYP3A Inducers
Avoid Ranexa in patients taking CYP3A inducers (rifampin, phenobarbital, phenytoin, carbamazepine, St. John's wort), as these reduce ranolazine levels and eliminate therapeutic efficacy 1.
3. Liver Cirrhosis (Any Child-Pugh Class)
Ranexa is contraindicated in all cirrhotic patients 1. Even mild cirrhosis (Child-Pugh Class A) increases ranolazine Cmax by 30%, while moderate cirrhosis (Class B) increases it by 80%. More critically, cirrhotic patients experience a 3-fold increase in QT prolongation that cannot be explained by pharmacokinetic changes alone, suggesting altered pharmacodynamics in hepatic impairment 1.
Important Warnings and Precautions (Not Absolute Contraindications)
Severe Renal Impairment
While not formally contraindicated, exercise extreme caution in severe renal impairment (CrCl <30 mL/min). A pharmacokinetic study was terminated early when 2 of 4 subjects developed acute renal failure requiring hemodialysis 1.
Clinical approach:
- Monitor renal function periodically in patients with moderate to severe renal impairment
- Discontinue immediately if acute renal failure develops
- Ranolazine exposure increases 40-50% across all degrees of renal impairment 2
QT-Prolonging Drugs
Although not listed as an absolute contraindication in the FDA label, avoid combining Ranexa with other QT-prolonging medications due to additive risk 4, 5. Ranolazine causes dose-dependent QTc prolongation.
Drug Interactions Requiring Dose Adjustment
Moderate CYP3A inhibitors (diltiazem, verapamil) increase ranolazine exposure 1.5-2-fold 2. These are not contraindications but require careful monitoring. Conversely, ranolazine increases digoxin levels by 40-60% through P-glycoprotein inhibition 2.
Populations Where Use is Not Established
- Pediatric patients: Safety and effectiveness not established 1
- Pregnancy: No human data available; use only if clearly needed 1
- Dialysis patients: Pharmacokinetics not assessed; hemodialysis unlikely to clear ranolazine (62% protein-bound) 1
Note: Heart failure (NYHA Class I-IV) and diabetes mellitus do not require dose adjustment and are not contraindications 1.